[Follicular lymphoma].

Area of Science:

• Hematology
• Oncology
• Immunology

Context:

• Follicular lymphoma (FL) is the most common indolent non-Hodgkin lymphoma.
• Current treatment strategies for FL are stratified by clinical presentation and disease burden.
• Understanding optimal therapeutic approaches is crucial for patient outcomes.

Purpose:

• To outline current first-line and relapsed/refractory treatment guidelines for follicular lymphoma.
• To differentiate therapeutic recommendations based on disease stage and tumor burden.
• To highlight the importance of re-biopsy and clinical trial enrollment for relapsed/refractory FL.

Summary:

• First-line therapy for localized FL involves local irradiation, offering long progression-free survival in 30-50% of cases.
• Low-tumor burden advanced-stage FL is typically managed with a watchful waiting strategy.
• High-tumor burden advanced-stage FL benefits from chemoimmunotherapy, with CHOP plus rituximab (R) and bendamustine plus R as potent options.

Impact:

• This stratification aids clinicians in selecting appropriate initial therapies for follicular lymphoma patients.
• Identifying patients who may benefit from specific chemoimmunotherapy regimens like bendamustine plus R.
• Emphasizes the need for re-evaluation and clinical trial participation in relapsed/refractory settings to advance FL treatment.